anti-Viral COVID 19 Spike RBD IgG/IgM Humanized Coronavirus Antibody | anti-COVID-19 antibody

Anti-SARS-CoV-2 Spike RBD IgG/IgM, Humanized antibody (Positive Control)

Cat. Num. AAA355896

• Reactivity: Viral
• Applications: Functional Assay, immunoassay, Lateral Flow
• Purity: Purity: >95% by HPLC & SDS-PAGE; Purification: Protein A purified
• Synonyms: COVID 19 Spike RBD IgG/IgM Humanized Coronavirus; Anti-SARS-CoV-2 Spike RBD IgG/IgM; Humanized antibody (Positive Control); 2019 Novel Coronavirus; Coronavirus; CoV; COVID-19 virus; HCoV-2; Human Coronavirus 2019; SARS2; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Spike RBD IgG/IgM; Receptor Binding Domain; anti-COVID-19 antibody

• Host: Cultured in vitro
• Reactivity: Viral
• Isotype: Human IgG+IgM (humanized antibodies)
• Clone Number: 2H4 (IgG) + 4H3 (IgM)
• Specificity: This product specifically recognizes the Spike RBD domain.
• Purity/Purification: Purity: >95% by HPLC & SDS-PAGE; Purification: Protein A purified
• Form/Format: Liquid; supplied in 0.01 M PBS without preservative.

• Applicable Applications for anti-COVID-19 antibody: Lateral Flow (rapid test) (LFA). Researchers are responsible for verifying the compatibility of this positive control antibody with the antigen/recombinant protein used in their immunoassay.
• Application Notes: Lateral flow (rapid test). This product is the prepared positive control for the assay.; ; Other applications have not been tested. The optimal dilutions should be determined by end user.
• Immunogen: Recombinant SARS-CoV-2 Spike RBD protein.
• Usage: Suggested protocol: Once the rapid test card is ready, pipette 10 ul of MBS355896 antibody product, then add 100 ul of sample diluent buffer into sample hole control (10ul/test). Note: MBS355896 is a mixture of anti-SARS-CoV-2 S-RBD IgG + anti-SARS-CoV-2 S-RBD IgM antibodies, optimized in ratios for use as a positive control for the development of rapid text/lateral flow assays.
• Dry Ice Shipment: Extra charge fee may add to your shipping cost as dry ice is required to ship this product.
• Preparation and Storage: Aliquot and store at -20°C for long term (at least for one year). Avoid repeated freeze and thaw cycles.

Related Product Information for anti-COVID-19 antibody

The 2019 novel coronavirus, abbreviated as 2019-ncov, is a new strain of coronavirus discovered in the human body in 2019. The symptoms of the virus are fever, fatigue, dry cough, and progressive dyspnea. In severe cases, the symptoms are acute respiratory distress syndrome, septic shock, metabolic acidosis and coagulation dysfunction that can’t be corrected. The virus has been confirmed to exist the phenomenon of human-to-human transmission, the shortest incubation period of the virus is only 1 day, and the longest incubation period is 14 days. The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2; DPP4, dipeptidyl peptidase-4; APN, aminopeptidase N; CEACAM, carcinoembryonic antigen-related cell adhesion molecule. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.

Product Categories/Family for anti-COVID-19 antibody

Infectious Diseases; Humanized Antibody

References

1. World Health Organization: Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: Interim Guidance.
2. "Pneumonia diagnosis and treatment program for novel coronavirus infection" of the National Health Commission of People’s Republic of China (Trial Version 3).
3. World Health Organization: Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: Interim Guidance.